logo
welcome
Reuters

Reuters

Unsupported price hikes added $815 million to US drug spending in 2023

Reuters
Summary
Nutrition label

80% Informative

Institute for Clinical and Economic Review ( ICER ) said five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence.

Gilead 's HIV drug Biktarvy , Novartis ' heart drug Entresto, Exelixis' cancer therapy Cabometyx and Pfizer 's rheumatoid arthritis drug Xeljanz were the other four drugs.

VR Score

91

Informative language

99

Neutral language

39

Article tone

formal

Language

English

Language complexity

59

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links